0000000000225006

AUTHOR

Savino M. Di Stasi

showing 10 related works from this author

Concordance and Clinical Significance of Uncommon Variants of Bladder Urothelial Carcinoma in Transurethral Resection and Radical Cystectomy Specimens

2014

To evaluate the concordance and prognostic role of histologic variants of bladder urothelial carcinoma in transurethral resection of bladder tumor (TURBT) and radical cystectomy (RC) specimens. METHODS Clinicopathologic information available at the time of RC and follow-up data from 4110 RC specimens, collected between January 2000 and December 2009 at 17 tertiary referral centers were retrospectively analyzed and evaluated for the presence or absence of uncommon variants of bladder urothelial carcinoma. The presence or absence of uncommon variants of bladder urothelial carcinoma was evaluated on previous TURBT specimens of patients undergoing RC. Cox regression was used to assess the impac…

MaleURINARY-BLADDER; CANCER; UPDATE; IMPACT; DIFFERENTIATIONIMPACTmedicine.medical_treatmentKaplan-Meier EstimateSettore MED/24 - UrologiaRetrospective StudieBladder cancer histologic variantsbladder urothelial carcinomaUrinary bladderMedicine (all)Middle AgedPrognosisCANCERDIFFERENTIATIONmedicine.anatomical_structureTreatment OutcomeUrinary Bladder Neoplasmbladder cancerFemaleHumanmedicine.medical_specialtyPrognosiConcordanceUrologyUrinary BladderUrologyCystectomyDisease-Free SurvivalFollow-Up StudieCystectomymedicineCarcinomaHumansClinical significanceAged; Carcinoma; Cystectomy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urology; Medicine (all)Proportional Hazards ModelsRetrospective StudiesAgedBladder cancerProportional hazards modelbusiness.industryCarcinomaAged; Carcinoma; Cystectomy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder NeoplasmsCancermedicine.diseaseUrinary Bladder NeoplasmsProportional Hazards ModelUPDATEURINARY-BLADDERbusinessFollow-Up Studies
researchProduct

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer

2018

PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.8…

Malemedicine.medical_treatmentPrognosis.030232 urology & nephrologyComorbidityGastroenterologySettore MED/24 - Urologia0302 clinical medicineBladder cancer; Body mass index; Obesity; PrognosisMedicineBody mass indexAged 80 and overHazard ratioBladder cancerCystoscopyMiddle AgedPrognosisTumor BurdenAdministration IntravesicalEditorialTransitional cell carcinomaChemotherapy Adjuvant030220 oncology & carcinogenesisBCG VaccineDisease ProgressionFemalemedicine.medical_specialtyPrognosiUrologyCystectomyDisease-Free SurvivalCystectomy03 medical and health sciencesAdjuvants ImmunologicInternal medicineHumansObesityMortalityAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCancer stagingCarcinoma Transitional CellBladder cancer; Body mass index; Obesity; Prognosis; UrologyScience & TechnologyBladder cancerbusiness.industryProportional hazards modelmedicine.diseaseUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisbusinessBody mass index
researchProduct

Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a …

2014

Contains fulltext : 153742.pdf (Publisher’s version ) (Closed access) BACKGROUND: The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. OBJECTIVE: To assess prognostic factors in patients who received bacillus Calmette-Guerin (BCG) as initial intravesical treatment of T1G3 tumors and to identify a subgroup of high-risk patients who should be considered for more aggressive treatment. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2451 T1G3 patients from 23 centers who received BCG between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable re…

OncologyMaleNon–muscle-invasive bladderBacillus Calmette-Guerin; BCG; Non-muscle-invasive bladder cancer; Prognostic factors; T1G3Settore MED/24 - UrologiaRisk groupsRetrospective StudieRisk FactorsBCGAge Factorskin and connective tissue diseasesBacillus Calmette-GuerinBacillus (shape)Prognostic factorbiologyBacillus Calmette-Gue´rin BCG Non–muscle-invasive bladder cancer Prognostic factors T1G3Age FactorsBacillus Calmette-Gue´rinMiddle AgedPrognosisTumor BurdenBacilluSurvival RateUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Urinary Bladder NeoplasmBCG VaccineDisease ProgressionFemaleNon muscle invasiveCalmette-GuérinCarcinoma in SituHumanmedicine.medical_specialtyPrognosiNon-muscle-invasive bladder cancerUrologyUrologyT1G3Prognostic factorsCystectomyRisk AssessmentNon–muscle-invasive bladder cancerFollow-Up StudieAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicinecancerHumansAgedRetrospective StudiesBladder cancerbusiness.industryRisk Factorbiology.organism_classificationmedicine.diseaseMulticenter studyUrinary Bladder NeoplasmsProper treatmentNeoplasm Recurrence LocalbusinessFollow-Up StudiesEuropean urology
researchProduct

Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer

2018

The aim of this multicenter study was to investigate the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and to validate the NLR cutoff of 3 in a large multi-institutional cohort of patients with primary T1 HG/G3 non-muscle-invasive bladder cancer (NMIBC).

High risk; High-grade; NLR; Progression; RecurrenceMaleNeutrophilsmedicine.medical_treatment030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineRecurrenceHigh-gradeRecurrence.LymphocytesHigh risk; High-grade; NLR; Progression; Recurrence; Oncology; UrologyAged 80 and overProgressionHigh riskMiddle AgedPrognosis3. Good healthAdministration IntravesicalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisCohortBCG VaccineDisease ProgressionFemaleNon muscle invasiveAdjuvantAdultmedicine.medical_specialtyUrologyUrologyCystectomyDisease-Free SurvivalNLRResection03 medical and health sciencesmedicineHumansLymphocyte CountNeutrophil to lymphocyte ratioAgedRetrospective StudiesScience & TechnologyBladder cancerbusiness.industryfungimedicine.diseaseConfidence intervalUrinary Bladder NeoplasmsMulticenter studyNeoplasm Recurrence LocalbusinessClinical Genitourinary Cancer
researchProduct

The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer

2016

BACKGROUND Potential differences in efficacy of different bacillus Calmette-Guerin (BCG) strains are of importance for daily practice, especially in the era of BCG shortage. OBJECTIVE To retrospectively compare the outcome with BCG Connaught and BCG TICE in a large study cohort of pT1 high-grade non-muscle-invasive bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS Individual patient data were collected for 2,451 patients with primary T1G3 tumors from 23 centers who were treated with BCG for the first time between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Using Cox multivariable regression and adjusting for the most important prognostic factors in this nonrandomiz…

Malemedicine.medical_treatmentIntravesical drug administration030232 urology & nephrologyKaplan-Meier EstimateBCG ConnaughtSettore MED/24 - Urologia0302 clinical medicineMaintenance therapyMedicine610 Medicine & healthhigh gradeAged 80 and overHazard ratioMiddle AgedAdministration IntravesicalTreatment OutcomeOncology030220 oncology & carcinogenesisCohortbladder cancerFemaleImmunotherapyNon muscle invasivemedicine.medical_specialtyrecurrenceUrologyBCG Connaught; BCG Tice; BCG vaccine; bladder cancer; high grade; Immunotherapy; Intravesical drug administration; progression; recurrence; T1G3; Oncology; UrologyT1G3ArticleMaintenance ChemotherapyBCG Connaught03 medical and health sciencesAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]HumansNeoplasm InvasivenessBCG vaccineAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryImmunotherapy ActiveBCG TiceImmunotherapymedicine.diseaseSurgeryUrinary Bladder NeoplasmsDrug EvaluationprogressionNeoplasm GradingbusinessBCG vaccineFollow-Up StudiesBCG Connaught; BCG Tice; BCG vaccine; Immunotherapy; Intravesical drug administration; T1G3; bladder cancer; high grade; progression; recurrenceUrologic Oncology: Seminars and Original Investigations
researchProduct

The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer tre…

2015

Objectives To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients and methods In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette–Gu erin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical out…

Malemedicine.medical_treatment030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineImmunologicRetrospective Studiehigh gradere-TURHazard ratioMiddle Agedmedicine.anatomical_structureAdministration IntravesicalTreatment Outcome030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]CohortUrinary Bladder NeoplasmBCG VaccineUrologic Surgical Proceduresbladder cancerFemaleHumanReoperationmedicine.medical_specialtyrecurrenceUrologyUrologyT1G3CystectomyArticleCystectomy03 medical and health sciencesbladder cancer; high grade; progression; re-TUR; recurrence; T1G3; UrologyAdjuvants ImmunologicUrethramedicineHumansAdjuvantsT1G3; bladder cancer; high grade; progression; re-TUR; recurrenceRetrospective StudiesAgedNeoplasm StagingBladder cancerbusiness.industryCancerRetrospective cohort studymedicine.diseaseSurgerybladder cancer; high grade; progression; re-TUR; recurrence; T1G3; Adjuvants Immunologic; Aged; BCG Vaccine; Cystectomy; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Reoperation; Retrospective Studies; Treatment Outcome; Urethra; Urinary Bladder Neoplasms; UrologyUrethraUrinary Bladder NeoplasmsprogressionNeoplasm GradingbusinessBCG vaccine
researchProduct

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer

2018

Background: Serum levels of neutrophils, platelets, and lymphocytes have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer (BC). Objective: To evaluate the prognostic role of the combination of the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) in patients with high-risk non–muscle-invasive urothelial BC (NIMBC). Design, setting, and participants: A total of 1151 NMIBC patients who underwent first transurethral resection of the bladder tumor (TURBT) at 13 academic institutions between January 1, 2002 and December 31, 2012 were included in this analysis. The median follow-up was 48 mo.…

OncologyMaleBladder cancer; Lymphocyte/monocyte ratio; Neutrophil/lymphocyte ratio; Platelet/lymphocyte ratio; Prognosis; Aged; Biomarkers Tumor; Blood Platelets; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Inflammation; Lymphocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Prognosis; Risk Factors; Urinary Bladder NeoplasmsNeutrophilsmedicine.medical_treatmentLymphocyte:Medicina Básica [Ciências Médicas]Prognosis.030232 urology & nephrologyMonocyteMonocytesSettore MED/24 - Urologia0302 clinical medicineRisk FactorsLymphocytesStage (cooking)Framingham Risk ScoreTumorNeutrophilBladder cancerPrognosis3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioCiências Médicas::Medicina BásicaDisease ProgressionLymphocyteFemalemedicine.symptomHumanBlood Plateletsmedicine.medical_specialtyPlatelet/lymphocyte ratioPrognosiUrologyInflammationCystectomyFollow-Up StudieCystectomy03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLymphocyte CountAgedInflammationCarcinoma Transitional CellBladder cancerScience & Technologybusiness.industryProportional hazards modelRisk FactorCarcinomaLymphocyte/monocyte ratioImmunotherapymedicine.diseaseUrinary Bladder NeoplasmsBlood PlateletSurgeryTransitional CellbusinessBiomarkersFollow-Up Studies
researchProduct

Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral…

2020

Objectives: The aim of this multicenter study was to investigate the prognostic role of type 2 diabetes mellitus (T2DM) comorbidity in a large multi-institutional cohort of patients with primary T1HG/G3 non–muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB). Materials and methods: A total of 1,172 patients with primary T1 HG/G3 who had NMIBC on re-TURB and who received adjuvant intravesical bacillus Calmette-Guérin therapy with maintenance were included. Endpoints were recurrence-free survival and progression-free survival. Results: A total of 231 (19.7%) of patients had T2DM prior to TURB. Five-year recurrence-free survival estimates were 12.5…

Malemedicine.medical_specialtyDiabetes mellituUrologymedicine.medical_treatment030232 urology & nephrologyUrologyCystectomyResection03 medical and health sciences0302 clinical medicineDiabetes mellitusHigh gradeAdjuvants ImmunologicUrethraRecurrenceDiabetes mellitusmedicineHumansIn patientNeoplasm InvasivenessAgedNeoplasm StagingRetrospective StudiesBladder cancerProgressionbusiness.industryHigh riskBladder cancerType 2 Diabetes MellitusMiddle Agedmedicine.diseasePrognosisComorbidityProgression-Free Survival3. Good healthBladder cancer; Diabetes mellitus; High grade; High risk; Progression; RecurrenceSettore MED/24OncologyDiabetes Mellitus Type 2Urinary Bladder NeoplasmsChemotherapy Adjuvant030220 oncology & carcinogenesisCohortBCG VaccineFemaleNeoplasm GradingbusinessAdjuvantUrologic oncology
researchProduct

Predictors of residual T1 high grade on re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-grade/grade…

2018

The aim of this multi-institutional study was to identify predictors of residual high-grade (HG) disease at re-transurethral resection (reTUR) in a large cohort of primary T1 HG/Grade 3 (G3) bladder cancer patients. A total of 1155 patients with primary T1 HG/G3 bladder cancer from 13 academic institutions that underwent a reTUR within 6 weeks after first TUR were evaluated. Logistic regression analysis was performed to assess the association of predictive factors with residual HG at reTUR. Residual HG cancer was found in 288 (24.9%) of patients at reTUR. Patients presenting residual HG cancer were more likely to have carcinoma in situ (CIS) at first resection (p=25 kg/m2. On multivariable …

Bladder cancer; High-grade; Neutrophil-to-lymphocytes ratio; Re-transurethral resection; Oncologymedicine.medical_specialty030232 urology & nephrologyUrologyOverweightResidualLogistic regressionSettore MED/24 - Urologia03 medical and health sciences0302 clinical medicineRe-transurethral resectionHigh-grademedicinehigh-grade2. Zero hungerBladder cancerScience & Technologybusiness.industryCarcinoma in situBladder cancerCancerre-transurethral resectionmedicine.disease3. Good healthre-transurethral resection.Oncology030220 oncology & carcinogenesisConcomitantCohortbladder cancermedicine.symptomNeutrophil-to-lymphocytes ratiobusinessneutrophil-to-lymphocytes ratioResearch Paper
researchProduct

High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study

2018

The aim of this multicenter study was to investigate the prognostic impact of residual T1 high-grade (HG)/G3 tumors at re-transurethral resection (TUR of bladder tumor) in a large multi-institutional cohort of patients with primary T1 HG/G3 bladder cancer (BC).

MaleTime Factorsmedicine.medical_treatment:Medicina Básica [Ciências Médicas]Treatment outcomeBladder cancer; High risk; High-grade; Second look resection; Transurethral resection of bladder tumor; Aged; Aged 80 and over; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Progression-Free Survival; Recurrence; Regression Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineRecurrenceHigh-grade80 and overAged 80 and overTransurethral resection of bladder tumorCARCINOMA TRANSITIONAL CELLHigh riskBladder cancerFollow up studiesMiddle AgedPrognosisProgression-Free Survival3. Good healthScholarshipTreatment OutcomeLocal030220 oncology & carcinogenesisCiências Médicas::Medicina BásicaUrinary Bladder NeoplasmDisease ProgressionRegression AnalysisUrologic Surgical ProceduresFemaleSecond look resectionHumanmedicine.medical_specialtyTime FactorPrognosiUrologyBladder cancer; High risk; High-grade; Second look resection; Transurethral resection of bladder tumorCystectomyRegression AnalysiDisease-Free SurvivalResectionFollow-Up StudieCystectomy03 medical and health sciencesbladder cancer; high risk; high-grade; second look resection; transurethral resection of bladder tumor; aged; aged 80 and over; carcinoma transitional cell; cystectomy; disease progression; disease-free survival; female; follow-up studies; humans; malemedicineHumansProgression-free survivalAgedCarcinoma Transitional CellScience & Technologybusiness.industryGeneral surgeryDisease progressionCarcinomaNeoplasm RecurrenceUrinary Bladder NeoplasmsUrologic Surgical ProcedureTransitional CellTransurethral resection of bladder tumor.Neoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct